Raloxifene

Generic Name: Raloxifene

Brand Names: Evista, Optruma, Raloxifene Teva

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₇NO_₄S

CAS Number: 84449-90-1

Unique Ingredient Identifier: YX9162EO3I

Background: Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labe...

Indication: Indicated for the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.

Indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.

Associated Conditions: Invasive Breast Cancer, Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment

Associated Therapies: -

Clinical Trials

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: raloxifene
Drug: lasofoxifene
Drug: Placebo

First Posted Date: 2005-09-13

Last Posted Date: 2011-08-12

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 540

Registration Number: NCT00163137

Locations: 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States

AFTER: Altering Fat Through Estrogen and Raloxifene

Phase 2

Completed

Conditions: Postmenopause

First Posted Date: 2005-09-08

Last Posted Date: 2009-12-02

Lead Sponsor: National Institute on Aging (NIA)

Target Recruit Count: 108

Registration Number: NCT00149604

Locations: 🇺🇸
University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States

Raloxifene in Preventing Breast Cancer in Premenopausal Women

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2005-06-23

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019500

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

Estrogen Alternatives Study

Phase 4

Completed

Conditions: Healthy

First Posted Date: 2005-04-15

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00108238

Locations: 🇺🇸
VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States

Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

First Posted Date: 2004-08-30

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Registration Number: NCT00004915

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Phase 4

Completed

Conditions: Postmenopausal Osteoporosis

First Posted Date: 2004-03-19

Last Posted Date: 2007-05-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 200

Registration Number: NCT00079924

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States

Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer
Menopausal Symptoms
Osteoporosis

First Posted Date: 2003-08-06

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 80

Registration Number: NCT00031811

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

First Posted Date: 2003-08-04

Last Posted Date: 2015-10-05

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 20

Registration Number: NCT00065767

Locations: 🇺🇸
University of Wisconsin Memory Research Program, Madison, Wisconsin, United States

Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 150

Registration Number: NCT00031850

Locations: 🇬🇧
Christie Hospital NHS Trust, Manchester, England, United Kingdom

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen
Drug: Raloxifene

First Posted Date: 2003-01-27

Last Posted Date: 2015-10-06

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 19747

Registration Number: NCT00003906

Locations: 🇺🇸
Santa Clarita Valley Cancer Center - UCLA, Valencia, California, United States
🇺🇸
Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

and more 513 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy